Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy
Daillere R, Derosa L, Bonvalet M, Segata N, Routy B, Gariboldi M, Budinska E, De Vries IJM, Naccarati AG, Zitvogel V, Caldas C, Engstrand L, Loilbl S, Fieschi J, Heinzerling L, Kroemer G, Zitvogel L (2020)
Publication Type: Journal article, Review article
Publication year: 2020
Journal
Book Volume: 9
Journal Issue: 1
DOI: 10.1080/2162402X.2020.1774298
Abstract
Accumulating evidence demonstrates the decisive role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade in preclinical tumor models, as well as in cancer patients. In synthesis, it appears that a normal intestinal microbiota supports therapeutic anticancer responses, while a dysbiotic microbiota that lacks immunostimulatory bacteria or contains overabundant immunosuppressive species causes treatment failure. These findings have led to the design of clinical trials that evaluate the capacity of modulation of the gut microbiota to synergize with treatment and hence limit tumor progression. Along the lines of this Trial Watch, we discuss the rationale for harnessing the gut microbiome in support of cancer therapy and the progress of recent clinical trials testing this new therapeutic paradigm in cancer patients.
Authors with CRIS profile
Involved external institutions
Istituto Italiano per la Medicina Genomica / Italian Institute for Genomic Medicine (IIGM)
Italy (IT)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Everimmune
France (FR)
Institut Gustave-Roussy
France (FR)
Università degli Studi di Trento
Italy (IT)
Centre hospitalier de l'Université de Montréal (CHUM)
Canada (CA)
Fondazione IRCCS: Istituto Nazionale dei Tumori
Italy (IT)
Masaryk University
Czech Republic (CZ)
Radboud University Nijmegen
Netherlands (NL)
University of Cambridge
United Kingdom (GB)
Karolinska Institute
Sweden (SE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
HalioDx - Luminy Biotech Entreprises
France (FR)
Italy (IT)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Everimmune
France (FR)
Institut Gustave-Roussy
France (FR)
Università degli Studi di Trento
Italy (IT)
Centre hospitalier de l'Université de Montréal (CHUM)
Canada (CA)
Fondazione IRCCS: Istituto Nazionale dei Tumori
Italy (IT)
Masaryk University
Czech Republic (CZ)
Radboud University Nijmegen
Netherlands (NL)
University of Cambridge
United Kingdom (GB)
Karolinska Institute
Sweden (SE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
HalioDx - Luminy Biotech Entreprises
France (FR)
How to cite
APA:
Daillere, R., Derosa, L., Bonvalet, M., Segata, N., Routy, B., Gariboldi, M.,... Zitvogel, L. (2020). Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. OncoImmunology, 9(1). https://dx.doi.org/10.1080/2162402X.2020.1774298
MLA:
Daillere, Romain, et al. "Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy." OncoImmunology 9.1 (2020).
BibTeX: Download